November 17, 2024

German Biotechnology Days 2025

German Biotechnology Days 2025
Go back

BioRN will be the hosting Bioregion for the upcoming German Biotechnology Days, which will take place in Heidelberg on 9-10 April 2025. 
Over two days, the ‘Who’s Who’ of the biotechnology sector will meet in Heidelberg to experience an exciting programme and take advantage of the numerous networking opportunities. BioRN will support BioDeutschland e.V as coordinator and organiser in providing innovative small and medium-sized biotechnology companies and their partners from industry, science, politics and society in Germany with a forum for knowledge exchange and networking.

It is also a great opportunity for our region to showcase the excellence and performance of our regional life science ecosystem to the world! 
Around 1000 guests from 21 nations are expected again and for the first time the conference language will be completely in English.

Join uns on the expo floor and book your stand. The following link will take you directly to the sponsoring packages: https://www.biotechnologietage.de/sponsoring/registration.html 

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

read more
Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

read more
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp